Management of postoperative pain by Wels, D
Anaesthesia Supplement: Management of postoperative pain
S25 Vol 54 No 3 Supplement 1S Afr Fam Pract 2012
Introduction
Postoperative pain is the most undesired consequence 
of surgery, and if not managed adequately, can lead 
to delayed recovery and increased hospital stay.1 
Surveys continue to reveal that postoperative pain is 
insufficiently managed throughout the first world, let alone 
in the Third World.2 An American survey over 20 years 
showed that only one in four patients had adequate 
relief of postoperative pain. This has led recovery room 
protocols to include pain as a fifth vital sign that needs 
to be addressed before patients are discharged to the 
ward.3 Opioid-sparing techniques are becoming more 
popular as they decrease the undesired side-effects from 
narcotic analgesics, especially since data now suggest 
that some patients who are treated with opioids may 
have paradoxical reactions, resulting in hyperalgesia, 
rather than analgesia.4,5 Treatment of pain has also moved 
to the preventive realm, and aims to block the afferent 
nociceptive bombardment of the central nervous system, 
before and during surgery. This prevents neurochemical 
changes that could lead to central sensitisation and 
chronic pain.6
The importance of an acute pain service in hospitals has 
been shown to be invaluable. These teams practise in the 
recovery room, as well as the wards, to ensure continued 
analgesia services after discharge from theatre. They also 
provide valuable information to medical staff on the use 
of patient controlled analgesia (PCA) systems, epidurals, 
indwelling nerve catheters, and optimal drug dosing and 
administration.7
Pathophysiology
The pathophysiology of postoperative pain is multifactorial, 
and predominantly of inflammatory nature from skin 
incision and tissue damage. Inflammatory cytokines, 
interleukins and prostaglandins produced from the 
arachidonic acid pathway induce a neuro-inflammatory 
soup, which sensitises peripheral Aδ and C fibres. 
Ischaemia from retraction of tissue, as well as disrupted 
blood supplies, contributes to pain significantly, and is 
characterised by low tissue pH and high lactate levels at 
the site of incision.8,9
Persistent postoperative pain
The phenomenon of pain that persists beyond the time of 
expected tissue healing after surgery is termed persistent 
postoperative pain. The incidence varies depending on 
the type of surgery.10 Procedures such as a mastectomy, 
thoracotomy, and hernia repair, have an incidence of 
persistent postoperative pain of 30-50%.11 Preoperative 
risk factors for developing persistent postoperative pain 
include anxiety, depression, sleep disturbances, and 
genetic susceptibility. Intraoperatively, the amount of 
tissue damage and ischaemia are good predictors of 
persistent postoperative pain.  Repeated surgery, as well 
as chemotherapy and radiotherapy, can contribute to 
persistent postoperative pain. Prevention of persistent 
postoperative pain appears to be possible by adequate 
pre-emptive and perioperative analgesia.12 The most 
effective regimens are multimodal, and combine regional 
techniques together with opioid and non-opioid drugs, 
including gabapentanoids, ketamine and alpha-2 
agonists.13
Opioids
Despite their undesirable side-effects, such as respiratory 
depression, nausea, vomiting, sedation and pruritus, as 
well as the possibility of paradoxical hyperalgesia, opioids 
still remain the treatment of choice for moderate-to-
severe postoperative pain.2 Their short onset of action, 
multiple parenteral routes of administration, and lack of 
ceiling effects (not all of them) makes them very useful in 
titration doses against pain.
Intraoperatively, nociception under anaesthesia is 
adequately controllable with potent synthetic opioids, 
such as sufentanil and remifentanil. It is the conversion 
to longer-acting and less potent opioids in recovery and 
the ward which requires a little skill and pharmacological 
expertise. This often involves administration of a bolus dose 
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intraoperatively, followed by small intravenous titrations in 
recovery.
Although intramuscular administration avoids the first-
pass metabolism, and provides a fairly rapid onset, 
they often result in plasma level peaks and troughs that 
lead to breakthrough pain between dosing intervals. 
Increased labour and staffing often contribute to delayed 
administration of prescribed doses.14,15 Therefore, PCA is 
far superior in the management of postoperative pain, 
especially in the ward.16 Several disposable PCA pumps 
are available in South Africa currently, and they are 
becoming the standard of care in procedures where 
moderate-to-severe postoperative pain is expected. 
Usually, opioids are employed in PCAs. However, cocktails 
with ketamine and antiemetics are often used. This 
decreases the dose of opioid required, and is particularly 
useful in obese patients with obstructive sleep apnoea, 
where opioids precipitate upper airway obstruction.17 In 
these patients, PCAs with short-acting opioids, such as 
fentanyl, are more appropriate than longer-acting drugs, 
such as morphine, as well as postoperative observation in 
a high-care environment.18
Neuraxial morphine provides excellent postoperative 
analgesia for up to 24 hours. Morphine is considered to be 
the gold standard, single-dose neuraxial opioid. Delayed 
respiratory depression remains a concern, and these 
patients need to be monitored in a high-care environment 
postoperatively. It is also important to note that additional 
opioids are to be administered cautiously after neuraxial 
morphine has been given. The optimal single-shot dose 
to be used is 0.075-0.15 mg for intrathecal use, and 2.5- 
3.75 mg for epidural use.19
An extended release epidural morphine, consisting 
of encapsulated lipid particles, has recently become 
available in the USA, and provides analgesia for up to 
48 hours after a single dose. Therefore, no catheter need 
be placed, and patients can be fully anticoagulated 
postoperatively.  However, respiratory depression still 
remains a concern.20
A new technology for the transdermal delivery of fentanyl 
allows for rapid absorbtion from a skin patch. The patch 
uses a low-intensity direct current (iontophoresis) for 
transfer from the skin to the systemic circulation. The 
device is patient controlled, and activates a demand 
dose of 40 μg of fentanyl, with a lockout time of 10 
minutes.21 Technical problems have resulted in its voluntary 
withdrawal from the US Food and Drug Administration, but 
the technology is under review, and a similar product may 
emerge on the market soon.
One of the problematic side-effects of opioids remains 
ileus and constipation. Peripherally acting μ receptor 
antagonists do not cross the blood brain barrier. Therefore, 
they have no effect on analgesia. However, they 
antagonise the peripheral effects, and promote a return 
of bowel movements after surgery. Methylnaltexone 
and alvimopan are both peripheral μ antagonists, but 
are not yet available in South Africa.22Adding a very low 
dose of naloxone to a PCA cocktail has similar effects, by 
preventing peripheral μ effects, and has little effect on 
analgesia.
A phenomenon in which opioids have a paradoxical 
effect, and cause painful stimuli to be more sensitive, 
is called opioid-induced hyperalgesia. Usually, this 
phenomenon was only observed in patients on chronic 
opioid treatment, but has been identified perioperatively 
in patients who received potent or high-dose opioids. The 
mechanism is different to that of opioid tolerance, but 
appears to involve activation of the N-methyl-D-aspartate 
(NMDA) receptor by the excitatory neurotransmitter, 
glutamate. Drugs antagonising the NMDA receptor 
appear to play a role in the management of opioid-
induced hyperalgesia.5
Ketamine
Perioperative intravenous ketamine has been used as 
an adjuvant to treat postoperative pain for decades. 
A recent review of 70 studies with 4 701 patients, 
confirmed that perioperative opioid consumption 
was lower, postoperative nausea and vomiting was 
decreased, and that ketamine was especially useful 
in very painful procedures such as thoracic and major 
orthopedic surgery. The analgesic effect of ketamine was 
independent of the type of intra-operative opioid, timing 
of ketamine administration, and ketamine dose.23
Anti-inflammatory drugs
Currently, the American Society of Anesthesiologists 
recommends a multimodal approach to postoperative 
analgesia which specifically states “unless contraindicated, 
all patients should receive an around-the-clock regimen 
of nonsteroidal anti-inflammatory drugs (NSAIDs), selective 
cyclooxygenase-2 inhibitors (coxibs) or paracetamol”.24
NSAIDs, coxibs and paracetamol are indicated for the 
relief of mild-to-moderate pain, but given in combination 
with opioids reduces the opioid consumption, and the 
adverse effects associated with opioid use.25
NSAIDs, coxibs and paracetamol are antipyretic, and 
analgesic, while NSAIDs and coxibs are anti-inflammatory. 
They work by inhibiting the products of the cyco-oxygenase 
pathway, both peripherally and centrally. The mechanism 
of paracetamol is less clearly understood, and seems to 
work via inhibition of central cyco-oxygenase enzymes, 
augmenting descending serotonergic pathways, 
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activation of cannabinoid receptors, and inhibiting nitric 
oxide pathways.26-29
Dexamethasone, given as a single intravenous dose at 
the induction of surgery, decreases acute postoperative 
pain.30 This is due to its inhibition of the cyclooxygenase 
and lipogygenase pathways, as well as the inhibition 
of expression of genes and release of proinflammatory 
enzymes.31 The ideal dose has not been established, but 
appears to be 0.1mg/kg.
Alpha-2 agonists
Clonidine and the more selective dexmedetomidine, 
have opioid-sparing, sedative and analgesic properties.32 
Unfortunately, the analgesic doses of these drugs cause 
significant side-effects in the form of sedation, hypotension 
and bradycardia. They are also very long-acting, and can 
cause delayed awakening after general anaesthesia. 
The analgesic properties are very alluring though! A dose 
of 0.4 μg/kg dexmedetomidine was comparable with 
60 μg/kg oxycodone to treat postoperative pain after 
laparascopic sterilisation.33
Intramuscular dexmedetomidine (1-1.5 μg/kg),  provides 
excellent premedication and causes minimal haemo-
dynamic changes.34 Peak plasma levels are reached 
1.5 hours after administration, and analgesia effects per-
sist beyond six hours.35
When supplemented to local anaesthetics, alpha-2 
agonists provide analgesia which outlasts the effect of the 
local anaesthetic. This makes regional techniques much 
more effective postoperatively.36 Dexmedetomidine and 
clonidine can be used epidurally and intrathecally with 
local anaesthetics, and have been shown to prolong and 
improve the quality of neuraxial blocks.37,38
Local anaesthetics
Peripheral regional anesthesia can be very effective in 
the treatment of postoperative pain, especially when 
catheters are left in situ for the continuous infusion of local 
anaesthetics. A significant decrease in opioid consumption 
leads to less nausea and vomiting, less sedation and early 
mobilisation.2 Perineural catheters and epidural catheters 
can be attached to patient-controlled devices for self-
administration of local anaesthetics. Interestingly, in a 
comparison exercise, patients preferred intravenous PCA 
analgesia to epidural PCA analgesia, even though the 
epidural group was associated with lower pain scores.16 
Extended-release local anaesthetics, encapsulated in 
liposomes and other media, are now available in the 
USA, which provide a slow release of agent over 72 hours. 
Injections of these local anaesthetics into incisions after 
surgery or nerve blocks provide prolonged nerve block 
and analgesia. Epidural and intrathecal use for these 
drugs has not been studied. There are some concerns 
about myotoxicity and neurotoxicity.39,40
Intravenous lignocaine as an intravenous bolus of 
1.5 mg/kg, followed by an infusion of up to 2 mg/kg/hour for 
24 hours postoperatively reduces analgesic requirements 
significantly, and has an opioid-sparing effect.41
Gabapentanoids
Gabapentin and pregabalin, used extensively in 
the treatment of chronic neuropathic pain, reduce 
postoperative pain if given pre- and perioperatively. 
Pre-emptive pregabalin decreases postoperative pain 
scores, opioid consumption, as well as opioid-related 
adverse effects. However, postoperative sedation is 
increased. The recommended dose is 150-300 mg po as 
a premedication.42-44
Conclusion
Adequate treatment of postoperative pain remains 
challenging. Since postoperative pain has a multimodal 
aetiology, a multimodal treatment regimen makes sense. 
Opioids are still the mainstay of treatment for moderate-
to-severe pain, but their adverse effects make them 
limiting. The combination of drugs with opioids, such as 
paracetamol and anti-inflammatory drugs, or ketamine 
and alpha-2 agonists, enables the use of less opioids. 
Premedication and perioperative administration of 
calcium anatagonists, such as pregabalin, also attenuate 
postoperative pain. Regional procedures are extremely 
effective in managing postoperative pain, and use of in-
dwelling catheters enables continued nerve blockade 
postoperatively. The most effective management of 
postoperative pain is performed by acute pain teams 
who monitor patients in the immediate postoperative 
period, as well as in the ward later.
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